AstraZeneca and Moderna Therapeutics announce exclusive agreement to develop pioneering messenger RNA Therapeutics™ in cardiometabolic diseases and cancer

AstraZeneca and Moderna Therapeutics announce exclusive agreement to develop pioneering messenger RNA Therapeutics™ in cardiometabolic diseases and cancer

March 21, 2013

 

AstraZeneca today announced an exclusive agreement with Moderna Therapeutics to discover, develop and commercialise pioneering messenger RNA therapeutics™ for the treatment of serious cardiovascular, metabolic and renal diseases as well as cancer. Messenger RNA therapeutics™ are an entirely new treatment approach that enables the body to produce therapeutic protein in vivo, opening up new treatment options for a wide range of diseases that cannot be addressed today using existing technologies.

Flagship Ventures and Merck Research Labs Form Strategic Collaboration to Foster Early-Stage Life Sciences Innovation

Flagship Ventures and Merck Research Labs Form Strategic Collaboration to Foster Early-Stage Life Sciences Innovation

April 10, 2012

Initiative combines Merck’s drug development expertise with Flagship’s experience in building early stage companies

Visterra Partners with A*STAR to Develop VIS513, a Monoclonal Antibody for Dengue

Visterra Partners with A*STAR to Develop VIS513, a Monoclonal Antibody for Dengue

May 21, 2015

- Key Development Activities of the Collaboration Will Be Conducted in Singapore -

Editas Medicine Presents Data from Multiple Therapeutic Discovery Programs Emerging from its Genome Editing Platform at the ASGCT Annual Conference

Editas Medicine Presents Data from Multiple Therapeutic Discovery Programs Emerging from its Genome Editing Platform at the ASGCT Annual Conference

May 18, 2015

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Editas Medicine, a leading genome editing company, today announced data from several emerging therapeutic discovery programs, as well as data from advancements in its technology platform. Together these data demonstrate the breadth of research underway at Editas Medicine to translate the promise of genome editing technology into new medicines. The data were presented at the 18th Annual American Society of Gene & Cell Therapy (ASGCT) Meeting in New Orleans.

FDA Fast Track Designation Granted to Luspatercept for the Treatment of Patients with Beta-Thalassemia

FDA Fast Track Designation Granted to Luspatercept for the Treatment of Patients with Beta-Thalassemia

May 18, 2015

SUMMIT, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) and Acceleron Pharma Inc. (NASDAQ:XLRN) today announced that the United States Food and Drug Administration (FDA) has granted Fast Track designations to luspatercept for two separate indications; the use of luspatercept for the treatment of patients with transfusion dependent beta-thalassemia and the use of luspatercept for the treatment of patients with non-transfusion dependent beta-thalassemia. Celgene and Acceleron are jointly developing luspatercept.

Agios Announces FDA Fast Track Designation Granted to AG-120 for Treatment of Patients with Acute Myelogenous Leukemia with an IDH1 Mutation

Agios Announces FDA Fast Track Designation Granted to AG-120 for Treatment of Patients with Acute Myelogenous Leukemia with an IDH1 Mutation

May 18, 2015

CAMBRIDGE, Mass., May 18, 2015 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to AG-120 for the treatment of patients with acute myelogenous leukemia (AML) who harbor an isocitrate dehydrogenase-1 (IDH1) mutation.

Denali Therapeutics Launches with Initial Investment to Discover and Develop Treatments for Neurodegenerative Diseases

Denali Therapeutics Launches with Initial Investment to Discover and Develop Treatments for Neurodegenerative Diseases

May 14, 2015

SAN FRANCISCO, May 14, 2015 – Denali Therapeutics Inc. (“Denali”), a new biotechnology company focused on developing effective therapies for neurodegenerative diseases, announced today that it has launched with an initial investment commitment of $217 million. Denali is based on the collaboration of world-class scientists, industry experts and investors.

Selecta and Genethon Collaborate to Create Next Generation Gene Therapies Using Selecta’s Synthetic Vaccine Particle Platform

Selecta and Genethon Collaborate to Create Next Generation Gene Therapies Using Selecta’s Synthetic Vaccine Particle Platform

May 13, 2015

Collaboration to pioneer first-of-a-kind gene therapies enabling multiple dosing

Sanofi Exercises Option on Second Therapeutic Program with Selecta Biosciences to Develop an Antigen-Specific Immunotherapy Based on Synthetic Vaccine Particle Technology

Sanofi Exercises Option on Second Therapeutic Program with Selecta Biosciences to Develop an Antigen-Specific Immunotherapy Based on Synthetic Vaccine Particle Technology

May 13, 2015

Celiac disease program added to 2012 alliance addressing immune disorders related to food and airborne allergens

Selecta eligible to receive payments totaling up to $300 million as well as up to double digit tiered royalties on product sales of immune tolerance product for each program under the alliance

Moderna #1 on CNBC Disruptor 50 List

Moderna #1 on CNBC Disruptor 50 List

May 12, 2015

CAMBRIDGE, Mass., May 12, 2015 — Moderna Therapeutics, a pioneer in the development of messenger RNA (mRNA) TherapeuticsTM, today announced it has been named the top Disruptor on the third-annual CNBC Disruptor 50 list. For the second year in a row, CNBC recognizes Moderna as one of the country’s most ambitious and innovative companies changing the economy and overall business landscape.